Stock M MED LIFE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Med Life S.A.

Equities

M

ROMEDLACNOR6

End-of-day quote Bucharest S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
4.115 RON +0.37% Intraday chart for Med Life S.A. +2.88% +3.39%
Apr. 03 Med Life S.A. (BVB:M) acquired an unknown majority stake in Personal Genetics Srl. CI
Feb. 29 Med Life S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2025.
  • Sales forecast by analysts have been recently revised upwards.

Weaknesses

  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
MED LIFE S.A. Stock Med Life S.A.
+3.39% 464M
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.41% 84.68B
B-
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.95% 81.12B
C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+11.62% 29.59B
C+
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.64% 16.73B
B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-1.39% 16.36B
A-
PURE HEALTH HOLDING Stock Pure Health Holding
-31.58% 11.77B - -
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+1.40% 11.72B
A-
DAVITA INC. Stock DaVita Inc.
+28.88% 11.71B
B-
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-0.88% 11.66B
A-
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. M Stock
  4. Ratings Med Life S.A.